Allspring Global Investments Holdings LLC grew its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 400.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 534,304 shares of the company's stock after acquiring an additional 427,573 shares during the period. Allspring Global Investments Holdings LLC owned about 0.06% of Dr. Reddy's Laboratories worth $8,373,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also modified their holdings of the business. Lester Murray Antman dba SimplyRich grew its stake in shares of Dr. Reddy's Laboratories by 465.6% in the fourth quarter. Lester Murray Antman dba SimplyRich now owns 37,423 shares of the company's stock worth $590,000 after acquiring an additional 30,806 shares in the last quarter. Augustine Asset Management Inc. grew its stake in shares of Dr. Reddy's Laboratories by 392.6% in the fourth quarter. Augustine Asset Management Inc. now owns 249,744 shares of the company's stock worth $3,943,000 after acquiring an additional 199,044 shares in the last quarter. POM Investment Strategies LLC lifted its position in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after purchasing an additional 1,820 shares during the last quarter. XY Capital Ltd purchased a new stake in shares of Dr. Reddy's Laboratories during the 4th quarter worth $1,061,000. Finally, Savant Capital LLC purchased a new stake in shares of Dr. Reddy's Laboratories during the 4th quarter worth $220,000. Institutional investors and hedge funds own 3.85% of the company's stock.
Dr. Reddy's Laboratories Stock Performance
RDY traded down $0.11 on Friday, reaching $13.34. The company had a trading volume of 1,581,422 shares, compared to its average volume of 1,801,156. Dr. Reddy's Laboratories Limited has a 1 year low of $13.16 and a 1 year high of $16.89. The stock has a market capitalization of $11.13 billion, a PE ratio of 21.23 and a beta of 0.50. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average price of $14.63 and a 200-day moving average price of $15.19.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, research analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
RDY has been the subject of several recent analyst reports. Nomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th. Barclays decreased their price objective on shares of Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. Finally, StockNews.com cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th.
View Our Latest Report on Dr. Reddy's Laboratories
About Dr. Reddy's Laboratories
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Recommended Stories
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
